Bookmark
Forward
QuickView for Meropenem (compound)
PubChem
| Name: | meropenem |
|---|---|
| PubChem Compound ID: | 441129 |
| Molecular formula: | C17H31N3O8S |
| Molecular weight: | 437.509 g/mol |
| Synonyms: |
MEPM; Meropenem trihydrate (JP15); Meropenem (USP); D02222; Merrem; Merrem (TN); Meropenem; 119478-56-7; Meropenem trihydrate
|
DrugBank
Identification
| Name: | meropenem |
|---|---|
| Name (isomeric): | DB00760 |
| Drug Type: | small molecule |
| Synonyms: |
Antibiotic SM 7338; Meropenemum [INN-Latin]; Meropenem anhydrous
|
| Brand: | Merrem I.V., Merrem, Meronem |
| Category: | Antibacterials for Systemic Use, Anti-Bacterial Agents |
| CAS number: | 119478-56-7 |
Pharmacology
| Indication: | For use as single agent therapy for the treatment of the following infections when caused by susceptible isolates of the designated microorganisms: <b>complicated skin and skin structure infections</b> due to <i>Staphylococcus aureus</i> (b-lactamase and non-b-lactamase producing, methicillin-susceptible isolates only), <i>Streptococcus pyogenes</i>, <i>Streptococcus agalactiae</i>, viridans group streptococci, <i>Enterococcus faecalis</i> (excluding vancomycin-resistant isolates), <i>Pseudomonas aeruginosa</i>, <i>Escherichia coli</i>, <i>Proteus mirabilis</i>, <i>Bacteroides fragilis</i> and <i>Peptostreptococcus</i> species; <b>complicated appendicitis and peritonitis</b> caused by viridans group streptococci, <i>Escherichia coli</i>, <i>Klebsiella pneumoniae</i>, <i>Pseudomonas aeruginosa</i>, <i>Bacteroides fragilis</i>, <i>B. thetaiotaomicron</i>, and <i>Peptostreptococcus</i> species. Also for use in the treatment of bacterial meningitis caused by <i>Streptococcus pneumoniae</i>, <i>Haemophilus influenzae</i> (b-lactamase and non-b-lactamase-producing isolates), and <i>Neisseria meningitidis</i>. |
|---|---|
| Pharmacology: | Meropenem is a broad-spectrum carbapenem antibiotic. It is active against Gram-positive and Gram-negative bacteria. Meropenem exerts its action by penetrating bacterial cells readily and interfering with the synthesis of vital cell wall components, which leads to cell death. |
| Mechanism of Action: |
The bactericidal activity of meropenem results from the inhibition of cell wall synthesis. Meropenem readily penetrates the cell wall of most Gram-positive and Gram-negative bacteria to reach penicillin-binding- protein (PBP) targets. Its strongest affinities are toward PBPs 2, 3 and 4 of Escherichia coli and Pseudomonas aeruginosa; a...
show more » |
| Protein binding: | Approximately 2%. |
| Biotransformation: | Primarily excreted unchanged. There is one metabolite which is microbiologically inactive. |
| Route of elimination: | Approximately 70% of the intravenously administered dose is recovered as unchanged meropenem in the urine over 12 hours, after which little further urinary excretion is detectable. |
| Half Life: | Approximately 1 hour in adults and children 2 years of age and older with normal renal function. Approximately 1.5 hours in children 3 months to 2 years of age. |
| Toxicity: | In mice and rats, large intravenous doses of meropenem (2200-4000 mg/kg) have been associated with ataxia, dyspnea, convulsions, and mortalities. |
| Affected organisms: | Enteric bacteria and other eubacteria |
Interactions
| Drug interaction: |
|
|---|
Targets
Enzymes
